BioCryst Pharmaceuticals BCRX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's accrued expenses?
- BioCryst Pharmaceuticals (BCRX) reported accrued expenses of $119.4M in Q1 2026.
- How has BioCryst Pharmaceuticals's accrued expenses changed year-over-year?
- BioCryst Pharmaceuticals's accrued expenses increased by 28.9% year-over-year, from $92.64M to $119.4M.
- What is the long-term trend for BioCryst Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's accrued expenses has grown at a 30.1% compound annual growth rate (CAGR), from $33.94M to $126.41M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.